Bioventus Inc. (BVS) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $10.14 (+2.74%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| May 7, 2025 | Chase Knickerbocker | Craig-Hallum | $15.00 | +47.9% |
| Oct 1, 2024 | Caitlin Cronin | Canaccord Genuity | $12.00 | +18.3% |
| Aug 7, 2024 | Chase Knickerbocker | Craig-Hallum | $12.00 | +18.3% |
| May 7, 2024 | William Plovanic | Canaccord Genuity | $8.00 | -21.1% |
| Mar 13, 2024 | Alex Nowak | Craig-Hallum | $9.00 | -11.2% |
Top Analysts Covering BVS
BVS vs Sector & Market
| Metric | BVS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +28.2% | +1150.2% | +14.9% |
| P/E Ratio | 31.12 | 6.84 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $603M | $605M | $607M | 4 |
| 2027-03-31 | $143M | $144M | $145M | 1 |
| 2027-06-30 | $164M | $164M | $165M | 2 |
| 2027-09-30 | $156M | $156M | $157M | 2 |
| 2027-12-31 | $178M | $179M | $180M | 1 |
| 2028-03-31 | $147M | $148M | $149M | 1 |
| 2028-06-30 | $177M | $178M | $179M | 1 |
| 2028-09-30 | $167M | $168M | $169M | 1 |
| 2028-12-31 | $192M | $193M | $194M | 1 |
| 2029-12-31 | $734M | $739M | $745M | 1 |
| 2030-12-31 | $789M | $795M | $802M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.55 | $0.75 | $0.86 | 4 |
| 2027-03-31 | $0.14 | $0.14 | $0.14 | 1 |
| 2027-06-30 | $0.23 | $0.23 | $0.23 | 1 |
| 2027-09-30 | $0.20 | $0.20 | $0.21 | 1 |
| 2027-12-31 | $0.27 | $0.28 | $0.28 | 1 |
| 2028-03-31 | $0.17 | $0.17 | $0.17 | 1 |
| 2028-06-30 | $0.33 | $0.33 | $0.33 | 1 |
| 2028-09-30 | $0.25 | $0.25 | $0.26 | 1 |
| 2028-12-31 | $0.33 | $0.33 | $0.34 | 1 |
| 2029-12-31 | $1.07 | $1.08 | $1.09 | 1 |
| 2030-12-31 | $1.21 | $1.22 | $1.23 | 1 |
Frequently Asked Questions
What is the analyst consensus for BVS?
The consensus among 2 analysts covering Bioventus Inc. (BVS) is Buy with an average price target of $13.00.
What is the highest price target for BVS?
The highest price target for BVS is $15.00, set by Chase Knickerbocker at Craig-Hallum on 2025-05-07.
What is the lowest price target for BVS?
The lowest price target for BVS is $8.00, set by William Plovanic at Canaccord Genuity on 2024-05-07.
How many analysts cover BVS?
2 analysts have issued ratings for Bioventus Inc. in the past 12 months.
Is BVS a buy or sell right now?
Based on 2 analyst ratings, BVS has a consensus rating of Buy (2.00/5) with a +28.2% upside to the consensus target of $13.00.
What are the earnings estimates for BVS?
Analysts estimate BVS will report EPS of $0.75 for the period ending 2026-12-31, with revenue estimated at $605M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.